Form 4: FibroGen CFO Acquires 525,000 Stock Options

FibroGen's Chief Financial Officer, David DeLucia, was granted 525,000 stock options on January 9, 2025.

Summary

• David DeLucia, the Chief Financial Officer of FibroGen Inc., was granted 525,000 stock options on January 9, 2025.
• The options have an exercise price of $0.6508 per share.
• The options vest quarterly over four years, starting from January 9, 2025.
• The options expire on January 8, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of four years is typical for such grants, encouraging long-term commitment.
• The exercise price is likely set at or near the market price at the time of the grant, which is a common practice.

Stakeholder Impact

• The stock option grant may positively impact shareholder sentiment by aligning management's interests with the company's long-term success.

Key Dates

Keywords

stock options, FibroGen, CFO, David DeLucia, equity, vesting, executive compensation